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Abstract 
Background: Although sentinel lymph node biopsy (SLNB) can accurately predict the status of axillary lymph node 
(ALN) metastasis, the high false‑negative rate (FNR) of SLNB is still the main obstacle for the treatment of patients who 
receive SLNB instead of ALN dissection (ALND). The purpose of this study was to evaluate the clinical significance of 
SLNB combined with peripheral lymph node (PLN) sampling for reducing the FNR for breast cancer and to discuss the 
effect of “skip metastasis” on the FNR of SLNB.
Methods: At Shandong Cancer Hospital Affiliated to Shandong University between March 1, 2012 and June 30, 2015, 
the sentinel lymph nodes (SLNs) of 596 patients with breast cancer were examined using radiocolloids with blue dye 
tracer. First, the SLNs were removed; then, the area surrounding the original SLNs was selected, and the visible lymph 
nodes in a field of 3–5 cm in diameter around the center (i.e., PLNs) were removed, avoiding damage to the structure 
of the breast. Finally, ALND was performed. The SLNs, PLNs, and remaining ALNs underwent pathologic examination, 
and the relationship between them was analyzed.
Results: The identification rate of SLNs in the 596 patients was 95.1% (567/596); the metastasis rate of ALNs was 
33.7% (191/567); the FNR of pure SLNB was 9.9% (19/191); and after the SLNs and PLNs were eliminated, the FNR 
was 4.2% (8/191), which was significantly decreased compared with the FNR before removal of PLNs (P = 0.028). 
According to the detected number (N) of SLNs, the patients were divided into four groups of N = 1, 2, 3, and ≥4; the 
FNR in these groups was 19.6, 9.8, 7.3, and 2.3%, respectively. For the patients with ≤2 or ≤3 detected SLNs, the FNR 
after removal of PLNs was significantly decreased compared with that before removal of PLNs (N ≤ 2: 14.0% vs. 4.7%, 
P = 0.019; N ≤ 3: 12.2% vs. 4.7%, P = 0.021), whereas for patients with ≥4 detected SLNs, the decrease in FNR was not 
statistically significant (P = 1.000). In the entire cohorts, the “skip metastasis” rate was 2.5% (15/596); the FNR caused 
by “skip metastasis” was 2.1% (4/191).
Conclusions: The FNR of SLNB was associated with the number of SLNs. For patients with ≤3 detected SLNs, PLN 
sampling can reduce the FNR of SLNB to an acceptable level of less than 5%. Because of the existence of the “skip 
metastasis” and distinct metastasis patterns, the FNR of SLNB cannot be completely eliminated.
Keywords: Breast cancer, Sentinel lymph node biopsy, Peripheral lymph node, False‑negative rate, Skip metastasis
© 2016 Han et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate 
if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Chinese Journal of Cancer
*Correspondence:  cjcptzws@126.com 
2 Department of Surgery, Shandong Breast Center of Prevention 
and Treatment, Shandong Cancer Hospital Affiliated to Shandong 
University, Shandong Academy of Medical Sciences, 440 Jiyan Road, 
Jinan 250117, Shandong, P.R. China
Full list of author information is available at the end of the article
Page 2 of 6Han et al. Chin J Cancer  (2016) 35:35 
Background
Breast cancer is a common cancer in China; the age-
standardized rate (ASR) of incidence is estimated to be 
23.2/100,000, and the ASR of mortality is approximately 
4.9/100,000 [1, 2]. To accurately stage breast cancer, 
it is necessary to know a patient’s axillary lymph node 
(ALN) status. ALN status is also one of the most impor-
tant indicators for determining the prognosis of patients 
with breast cancer and guiding axillary treatment. Axil-
lary lymph node dissection (ALND) is an important 
part of the surgical treatment of invasive breast can-
cer; moreover, ALND is the most accurate method of 
evaluating the status of ALN metastasis. Patients with 
negative ALN status do not benefit from ALND, which 
increases the incidence of postoperative complications 
such as lymphedema and sensory and motor dysfunction. 
Greater awareness of breast cancer prevention and new 
treatment technologies have resulted in a higher propor-
tion of patients with early-stage breast cancer. The tumor 
load of the regional lymph nodes has also decreased [3, 
4], making it possible to narrow the range of patients who 
undergo axillary surgery.
In the 1990s, sentinel lymph node biopsy (SLNB) 
emerged as a new surgical procedure replacing the 
ALND of breast cancer, and “axilla-conserving” guid-
ance measures were implemented. For sentinel lymph 
node (SLN)-negative patients with breast cancer, large-
scale clinical trials have confirmed that SLNB and ALND 
result in no significant difference in terms of disease-free 
survival, overall survival, and recurrence-free survival 
[5–7]; other studies have shown that SLNB can accu-
rately predict the metastasis of ALNs [8, 9]. In principle, 
SLN-negative patients can forego ALND, but false-nega-
tive results are still the main concern of physicians as well 
as patients who undergo SLNB instead of ALND. In 2014, 
the American Society of Clinical Oncology reported 
six trials of SLNB; in these trials, the false-negative rate 
(FNR) was between 4.6% and 16.7% [10]. Kim et  al. [9] 
performed a meta-analysis and concluded that the aver-
age FNR of SLNB was 8.4% (range, 0%–29%). The Ameri-
can Society of Breast Surgeons established a task force 
to suggest acceptable standards for SLNB. In 2000, the 
task force recommended that the identification rate for 
SLNB be 85% or higher and that the FNR be 5% or lower 
[11]. Other studies demonstrated that, with the increase 
of the number of SLNs, the FNR of SLNB significantly 
decreased [12–14]. We conducted a prospective study of 
596 patients with breast cancer who received SLNB com-
bined with peripheral lymph node (PLN) sampling. To 
reduce the FNR, we attempted to increase the number of 
resected lymph nodes within a reasonable surgical field. 
There are many reasons for false-negative SLNB results; 
the phenomenon of “skip metastasis” [15] inevitably 
causes false negatives. This study also discusses the influ-
ence of “skip metastasis” on the FNR of SLNB.
Patients and methods
Patient selection and clinical data
The inclusion criteria for patients in the present study 
were as follows: (1) breast cancer confirmed by fine nee-
dle aspiration or biopsy; (2) preoperative clinical exami-
nation and imaging examination confirmed that the cases 
were cN0; (3) no anti-cancer therapy received before sur-
gery; (4) after the SLNs and PLNs were resected (whether 
or not there was metastasis), patients underwent level I 
combined with level II lymph node dissection or com-
plete ALND (including levels I, II, and III lymph nodes). 
Given these inclusion criteria, 596 patients with breast 
cancer who were treated at Shandong Cancer Hospital 
Affiliated to Shandong University, Shandong Province, 
China, between March 3, 2012 and June 30, 2015, were 
included in this study. All patients were women, aged 
26–77  years, with an average age of 48.7  years and a 
median age of 41  years. In 367 patients, the tumor was 
located in the upper outer quadrant; in 83 patients, in 
the lower outer quadrant; in 73 patients, in the upper 
inner quadrant; in 30 patients, in the lower inner quad-
rant; and in 43 patients, in the central area. Of all 596 
patients, 502 underwent breast resection plus ALND, 
and 94 patients underwent breast-conserving surgery. 
This study was approved by the ethics committee of the 




Blue dye combined with radionuclide was used for all 
SLNBs. Six to 18 h preoperatively, patients were injected 
with 99mTc–Sc-labeled sulfur colloid (Beijing Shihong 
Pharmaceutical Center, Beijing, China) into the sub-
cutaneous tissue around the tumor or breast paren-
chyma. The injection volume was 18.5–37  MBq. The 
Gamma Detection System (Neoprobe 2000, Dublin, 
OH, USA) was used preoperatively to detect the distri-
bution of hot spots in the axillary and internal mam-
mary region, and the gamma count of the injected site 
was recorded. After anesthesia, 1–2  mL of 1% methyl-
ene blue (Jiangsu Jumpcan Pharmaceutical Co., Taixing, 
Jiangsu, China) was subcutaneously injected in a single 
point around the tumor or in the nipple areola; the sur-
gery began 10–15  min later. During the operation, we 
generally found the blue-stained lymphatics on the lat-
eral border of the pectoralis major muscle, through the 
blue-stained lymph tube. We separated and removed the 
blue-stained lymph nodes and recorded their value using 
the gamma probe. Finally, we detected the entire axillary 
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area (including the blue-stained lymph nodes), searched 
for the entire ALN radioactive peak, and separated those 
lymph nodes with a radiation intensity greater than the 
lowest radioactivity of the blue-stained lymph nodes or 
higher than 10% of the radioactivity peak.
Operation steps and the definition of SLNs and PLNs
SLNs detected by dye and isotope were cut out, and the 
first SLN encountered was removed. To delineate the 
scope of the PLNs, we also removed the lymph nodes 
in a field of 3–5  cm in diameter around the SLNs. To 
avoid destroying the surrounding nerves and blood ves-
sels, blunt separation was performed within the range of 
fat connective tissue to remove the visible lymph nodes. 
The operation steps were as follows: (1) the lymph nodes 
found through blue-stained lymphatics were classified as 
SLNs, whether the gamma detection value was high or 
low; (2) the lymph nodes with radiation intensity greater 
than 10% of the peak were also referred to as SLNs, 
regardless of whether they were blue-stained; and (3) the 
remaining lymph nodes were classified as the PLNs. After 
removing the PLNs and the SLNs, the complete ALND 
or level I combined with level II lymph node dissection 
was carried out according to the situation. We conducted 
a pathologic examination of the SLNs, PLNs, and levels I, 
II, and III lymph nodes.
Statistical analysis
SPSS 19.0 software (IBM Co., Chicago, IL, USA) was 
used for all statistical analyses, and the results were 
evaluated per the University of Louisville SLNB tech-
nique criteria [16]. The identification rate = the number 
of SLNs identified/the number of patients who under-
went SLNB × 100%; FNR = the number of false-negative 
cases/the number of true-positive plus false-negative 
cases × 100%; sensitivity =  the number of true-positive 
cases/the number of true-positive plus false-negative 
cases × 100%; accuracy rate =  the number of true-neg-
ative plus true-positive cases/the number of patients 
who underwent SLNB ×  100%; and negative predictive 
value = the number of true-negative cases/the number of 
true-negative plus false-negative cases × 100%.
A Chi square test was used to compare the sample rate, 
as well as Fisher’s exact test with α = 0.05. The four-fold 




SLNs were detected in 567 out of 596 patients; the iden-
tification rate was 95.1% (567/596). For the 567 patients 
in whom SLNs were detected, the number of detected 
SLNs was 1–6, and a total of 1026 SLNs were dissected, 
with an average of 1.81 SLNs per patient (median, 2). 
From the surrounding tissues (including PLNs), 0–9 
lymph nodes were detected; a total of 1281 PLNs were 
dissected, with an average of 2.26 lymph nodes per 
patient (median, 3). Of these 567 patients, 191 had ALN 
metastasis, and 376 had no ALN metastasis. According 
to the detection number (N) of SLNs, the patients were 
divided into four groups of N = 1, 2, 3, and ≥4 (Table 1). 
For the 567 patients who underwent SLNB, the FNR was 
9.9% (19/191); the sensitivity was 90.1% (172/191); the 
accuracy rate was 96.6% (548/567); and the negative pre-
dictive value was 95.2% (376/395), as shown in Table  2. 
When SLNB was combined with PLN sampling, the FNR 
was 4.2% (8/191); the sensitivity was 95.8% (183/191); the 
accuracy rate was 98.6% (559/567); and the negative pre-
dictive value was 97.9% (376/384), as shown in Table  3. 
The difference in FNR before and after PLN sampling was 
statistically significant (P = 0.028; Table 4).
The association between the number of detected SLNs 
and FNR
The FNR observed in the N = 1, 2, 3, and ≥4 groups was 
19.6, 9.8, 7.3, and 2.3%, respectively (Table 4); the differ-
ence was statistically significant (χ2 = 7.856, P = 0.049). 
The FNR for pure SLNB was higher than 5% in the 
N = 1, 2, and 3 groups. When SLNB was combined with 
PNR sampling, the FNR was 14.0% for the N ≤ 2 group. 
After PLNs were removed, the FNR decreased to 4.7%; 
this reduction in the FNR was statistically significant 
(χ2 =  5.515, P =  0.019). For the N ≤  3 group, the FNR 
was 12.2%. After PLNs were removed, the FNR decreased 
to 4.7%; this reduction was also statistically significant 
(χ2 = 5.286, P = 0.021). No significant FNR decrease was 
observed in the N ≥ 4 group (P = 1.000; Table 4).
The association between “skip metastasis” and FNR
In this study, 15 patients had “skip metastasis.” Among 
these 15 patients, 3 had level I (−), II (+), and III (−); 1 
Table 1 Grouping based on the number of SLNs
Abbreviations: SLN sentinel lymph node, ALN axillary lymph node, nSLN non-
sentinel lymph node, PLN peripheral lymph node
ALN status No. of patients No. of SLNs
1 2 3 ≥4
Negative ALNs 376 112 111 89 64
Positive ALNs
 SLN(+) and nSLN(+) 72 19 22 14 17
 SLN(+) and nSLN(–) 100 18 33 24 25
 SLN(–) and PLN(+) 11 7 3 1 0
 SLN(–) and PLN(–) 8 2 3 2 1
 Total 567 158 172 130 107
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had level I (−), II (−), and III (+); and 11 had level I (+), 
II (−), and III (+). The occurrence rate of “skip metasta-
sis” was 2.5% (15/596). After SLNB was combined with 
PLN sampling, eight patients had false-negative results; 
among these eight patients, four had “skip metastasis.” 
The FNR caused by “skip metastasis” accounted for 2.1% 
(4/191) of cases.
Discussion
In the present study, the FNR of SLNB was 9.9% (19/191), 
which is within an average level. The FNR was signifi-
cantly reduced to 4.2% (8/191) after SLNB was combined 
with PLN sampling (P = 0.028). According to the group-
ing by the number of detected SLNs, for the patients 
with ≤2 or ≤3 detected SLNs, the FNR after removal of 
PLNs was significantly decreased compared with that 
before removal of PLNs (P  =  0.019 and 0.021, respec-
tively) and reached an acceptable level of less than 5%. 
For the patients with ≥4 detected SLNs, after the PLNs 
were removed, the FNR did not change (2.3% vs. 2.3%, 
P = 1.000). Our previous results showed that for patients 
with ≥4 detected SLNs, the FNR of SLNB was 1.9%, and 
the accuracy rate was 98.7% [14]. Thus, we conclude that 
SLNB can predict the state of ALNs, and it is not nec-
essary to carry out PLN sampling for patients with ≥4 
detected SLNs. The FNR caused by “skip metastasis” in 
this study accounted for 2.1% (4/191); “skip metastasis” 
will result in false negative results of SLNB, which cannot 
be completely eliminated.
Many researchers have confirmed the association 
between the number of detected SLNs and the FNR of 
SLNB. The American College of Surgeons Oncology 
Group Z1071 trial found that for patients with 2 and ≥3 
detected SLNs, the FNR of SLNB was 21.1% and 9.1%, 
respectively (P  =  0.007) [13]. Yi et  al. [17] found that 
when the number of SLNs reached 5, generally more 
than 99% positive SLNs could be found, which is similar 
to our finding. We found that, with an increased number 
of SLNs, the FNR of SLNB decreased (P  =  0.049); but 
after grouping patients based on the number of detected 
SLNs, the FNR of SLNB could be reduced to less than 5% 
by PLN sampling for those with ≤3 detected SLNs.
Most breast cancers follow the metastasis route of level 
I → level II → level III, and the metastasis of discontinu-
ous pattern also exists in some patients. According to 
previous studies, the metastasis rate of the interpectoral 
nodes was 2.6% to 25.9% [18, 19], whereas the incidence 
of “skip metastasis” was between 1.5% and 19.2% [20–22]. 
If SLNB was performed on patients with “skip metasta-
sis,” false-negative results may have also occurred [22, 
23]. Breast cancer metastases may also first invade the 
internal mammary lymph nodes (IMLNs). In the mid-
20th century, the study of radical mastectomy in breast 
cancer showed that the overall metastasis rate of IMLNs 
was 18% to 33%; most patients had ALN metastasis, and 
pure IMLN metastasis was 2% to 11% [24–26]. If meta-
static tumor cells move through the IMLN chain or “skip 
metastasis” jumps over axillary level I, or directly metas-
tasizes to level II and III of lymph nodes, a conventional 
Table 2 ALN metastasis state of  567 patients detected 
by SLNB
For SLNB, the FNR was (b)/(a+ b) = 19 (172+19) = 9.9%. Sensitivity 
was (a)
/
(a+ b) = 172 (172+19) = 90.1%. Accuracy rate was 
(a+d)
/
(a + b+c+d) = (172 + 376)
/
(172+19+0+376) = 96.6%. Negative 





Abbreviations: ALN axillary lymph node, SLNB sentinel lymph node biopsy, SLN 
sentinel lymph node, FNR false-negative rate
SLN status ALN status Total
(+) (–)
(+) 172 (a) 0 (c) 172
(–) 19 (b) 376 (d) 395
Total 191 376 567
Table 3 ALN metastasis state of  567 patients detected 
with SLNB and PLN sampling




























= (183 + 376)
/
(183+8+0+376) = 98.6%. Negative 













Abbreviations: ALN axillary lymph node, SLNB sentinel lymph node biopsy, PLN 
peripheral lymph node, SLN sentinel lymph node, FNR false-negative rate
SLN + PLN status ALN status Total
(+) (–)
(+) 183 (a′) 0 (c′) 183
(–) 8 (b′) 376 (d′) 384
Total 191 376 567
Table 4 FNR comparison before and after PLN sampling
Abbreviations: FNR false-negative rate, PLN peripheral lymph node, SLNB 










N = 1 158 19.6 4.3 5.059 0.024
N = 2 172 9.8 4.9 0.480 0.488
N = 3 130 7.3 4.9 <0.001 1.000
N ≥ 4 107 2.3 2.3 <0.001 1.000
Total 567 9.9 4.2 4.822 0.028
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SLNB will produce a false-negative result. Considering 
current SLNB technology and the route of breast can-
cer lymphatic metastasis, we conclude that false-nega-
tive results of SLNB cannot be completely eliminated. 
Regardless of the methods performed (such as increas-
ing the number of detected SLNs) to reduce the FNR 
of SLNB, because of the “skip metastasis” and distinct 
metastasis patterns of the lymph nodes in patients with 
breast cancer, there is a threshold past which the FNR 
of SLNB will not further decrease. In our study, the inci-
dence of “skip metastasis” was 2.5% (15/596), which is at 
a “low level” of the normal range as reported in the lit-
erature; this is because only cN0 patients were enrolled 
in our study. Of the eight patients who had false-negative 
results after SLNB was combined with PLN sampling, 
“skip metastasis” occurred in four patients, and the FNR 
caused by “skip metastasis” accounted for only 2.1% 
(4/191). If the FNR is at a low level (less than 5%), SLNB 
is a reasonable alternative to ALND. Despite “skip metas-
tasis” and distinct metastasis patterns, the resulting FNR 
is still in the acceptable range of less than 5%.
The present study had several limitations. First, PLN 
sampling performed in the area of a 3- to 5-cm diameter 
around the first traced SLN was only a clinical experi-
ment to consider the lymphatic distribution in breast tis-
sue. Currently, we have no proven parameters to explain 
this distance, and the anatomy of the lymph drainage 
route in this area needs to be studied further. Second, 
the sample size of an individual group was small after 
patients were grouped based on the number of detected 
SLNs, so a large study sample is needed for further 
validation.
Treatment of breast cancer has changed considerably 
since the beginning of the 21st century. From the largest 
tolerable treatment to the most minimally effective treat-
ment, the temporal treatment trend for the local ALNs of 
breast cancer patients has been towards less use of axil-
lary dissection [27]. Removing the PLNs located within a 
certain distance around the SLNs can effectively reduce 
the FNR of SLNB, which can enhance the understanding 
of SLNs and support the use of the SLNB combined with 
PLN sampling to decrease the FNR. Nevertheless, given 
the current SLNB technology and the phenomenon of 
“skip metastasis,” we recognize that the FNR of SLNB will 
not decrease to zero. Thus, using a combination of patho-
logic and biological tumor characteristics as predictors 
of ALN status could become another trend [27]. Future 
studies should include patient follow-up and prognostic 
evaluation.
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